CEO Tim Wilson describes the rationale for focusing on IgE, and why the company has chosen folate receptor alpha as its first target....

Bob Duggan and Maky Zanganeh answer questions relating to China derived data, designing U.S. studies, how to scale the development of the...

CEO Thomas Soloway and CTO Elisa Kieback walk us through what makes T-knife unique in the construction and manufacturing of its cell...

From Berlin, he describes the various isotopes that are used in medicines and discusses the technological advances that have lead to a...

CEO Eric Dube describes the drug's mechanism, the new population, and what else Travere is working on that will have near-term catalysts.

Pierre d'Epenoux describes how activating butyrophilin modulates γδ t-cells, science that has largely been explored in Marseille, and...

Hervé Brailly covers lacutamab, monalizumab, the company's NK engager programs, and more.

CEO Rodolphe Clerval describes the scientific rationale, and how Coave has engineered this to be easy to add at the end of vector...

CEO Stéphane Boissel describes the company's first gene therapy program, with seeks to treat retinitis pigmentosa regardless of the...

CEO Pierre Belichard describes the scientific underpinnings of this idea, and how it has lead to Enterome's programs, including one in...

CEO John Furey describes how the therapy works, like a combination of "immunotherapy and cell therapy." He reviews phase 1 data, and...

CEO Nicolas Poirier describes the work, which includes an IL-7R, and partnerships with AbbVie, Boehringer Ingelheim, and Veloxis.

Founder and CEO Laurent Levy gives an update on the company's robust radiation oncology program, and describes two new areas of...

Samir Ounzain explains the way HAYA studies how long non-coding RNAs, a once poorly understood component of the genome, affects disease...

Bobby Azamian describes how Tarsus has expanded its salesforce by 50%, and will be adding a DTC element to the launch and derive...

Dr. Greenstreet shares her opinion of why she believes the data places vutrisiran in a competitive position to be a first line choice for...

He describes Skye's CB1 program and the rationale for targeting fat tissue, and why today's versions of these therapies could be better...

He describes why this may be a good time to asset hunt, but also why Roivant has been conservative with its cash. Plus upcoming catalysts...

He describes what the funds will enable Artiva to do in the clinic, and why he believes the company's non-modified NK cell approach is...

Marcio Souza describes Praxis' small molecule and antisense oligonucleotide platforms, and previews key trials that will have near term data